Literature DB >> 33681089

NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2.

Marinko Marušić1,2,3, Matej Paić1, Mia Knobloch1, Ana-Marija Liberati Pršo4.   

Abstract

Nonalcoholic fatty liver disease is a condition defined by fat accumulation in hepatocytes not promoted by excessive alcohol consumption. It is highly prevalent and is strongly associated with insulin resistance, metabolic syndrome, and diabetes type II. Insulin resistance plays a crucial role in the multifactorial etiopathogenesis of this condition leading to accumulation of free fatty acids in the liver cells, thus causing lipotoxicity, inflammation, and fibrosis. In this review, we will focus on currently known pathogenesis of nonalcoholic fatty liver disease. Numerous investigation strategies are available to establish the diagnosis, from biochemical markers and ultrasound to various molecular and advanced imaging techniques and liver biopsy. Prevention is crucial. However, effective and promising therapies are strongly demanded.
Copyright © 2021 Marinko Marušić et al.

Entities:  

Year:  2021        PMID: 33681089      PMCID: PMC7904371          DOI: 10.1155/2021/6613827

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  77 in total

1.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

Authors:  T Ueno; H Sugawara; K Sujaku; O Hashimoto; R Tsuji; S Tamaki; T Torimura; S Inuzuka; M Sata; K Tanikawa
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

Review 2.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

3.  The role of the gut microbiota in nonalcoholic fatty liver disease.

Authors:  Ahmed Abu-Shanab; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

Review 4.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

Review 5.  Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids.

Authors:  C L Rock; R A Jacob; P E Bowen
Journal:  J Am Diet Assoc       Date:  1996-07

6.  Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

Authors:  Giovanni Musso; Maurizio Cassader; Elena Paschetta; Roberto Gambino
Journal:  JAMA Intern Med       Date:  2017-05-01       Impact factor: 21.873

7.  Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Authors:  H Z Lin; S Q Yang; C Chuckaree; F Kuhajda; G Ronnet; A M Diehl
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  Adherence to the Mediterranean diet is associated with lower abdominal adiposity in European men and women.

Authors:  Dora Romaguera; Teresa Norat; Traci Mouw; Anne M May; Christina Bamia; Nadia Slimani; Noemie Travier; Herve Besson; Jian'an Luan; Nick Wareham; Sabina Rinaldi; Elisabeth Couto; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Vanessa Cottet; Domenico Palli; Claudia Agnoli; Salvatore Panico; Rosario Tumino; Paolo Vineis; Antonio Agudo; Laudina Rodriguez; Maria Jose Sanchez; Pilar Amiano; Aurelio Barricarte; Jose Maria Huerta; Timothy J Key; Elisabeth A Spencer; H Bas Bueno-de-Mesquita; Frederike L Büchner; Philippos Orfanos; Androniki Naska; Antonia Trichopoulou; Sabine Rohrmann; Rudolf Kaaks; Manuela Bergmann; Heiner Boeing; Ingegerd Johansson; Veronica Hellstrom; Jonas Manjer; Elisabet Wirfält; Marianne Uhre Jacobsen; Kim Overvad; Anne Tjonneland; Jytte Halkjaer; Eiliv Lund; Toni Braaten; Dragun Engeset; Andreani Odysseos; Elio Riboli; Petra H M Peeters
Journal:  J Nutr       Date:  2009-07-01       Impact factor: 4.798

9.  Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

Authors:  Siddharth Verma; Donald Jensen; John Hart; Smruti R Mohanty
Journal:  Liver Int       Date:  2013-06-13       Impact factor: 5.828

Review 10.  Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?

Authors:  Shaheen Tomah; Naim Alkhouri; Osama Hamdy
Journal:  Clin Diabetes Endocrinol       Date:  2020-06-05
View more
  8 in total

1.  Curcumin Derivative MTH-3 Regulates Palmitate-induced Insulin Resistance in Mouse Myoblast C2C12 Cells.

Authors:  Yu-Jen Chiu; Yu-Hsiang Lo; Jai-Sing Yang; Sheng-Chu Kuo; Shih-Chang Tsai
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 2.  Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future.

Authors:  João Paulo Margiotti Dos Santos; Mariana Canevari de Maio; Monike Alves Lemes; Lucas Fornari Laurindo; Jesselina Francisco Dos Santos Haber; Marcelo Dib Bechara; Pedro Sidnei do Prado; Eduardo Costa Rauen; Fernando Costa; Barbara Cristina de Abreu Pereira; Uri Adrian Prync Flato; Ricardo de Alvares Goulart; Eduardo Federighi Baisi Chagas; Sandra Maria Barbalho
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

3.  IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study.

Authors:  Xu Chen; Yi Tang; Shen Chen; Wenhua Ling; Qing Wang
Journal:  Endocr Connect       Date:  2021-10-13       Impact factor: 3.335

4.  Evaluation of a Whole-Liver Dixon-Based MRI Approach for Quantification of Liver Fat in Patients with Type 2 Diabetes Treated with Two Isocaloric Different Diets.

Authors:  Valentina Brancato; Giuseppe Della Pepa; Lutgarda Bozzetto; Marilena Vitale; Giovanni Annuzzi; Luca Basso; Carlo Cavaliere; Marco Salvatore; Angela Albarosa Rivellese; Serena Monti
Journal:  Diagnostics (Basel)       Date:  2022-02-16

5.  Integration of genetic colocalizations with physiological and pharmacological perturbations identifies cardiometabolic disease genes.

Authors:  Michael J Gloudemans; Brunilda Balliu; Daniel Nachun; Theresia M Schnurr; Matthew G Durrant; Erik Ingelsson; Martin Wabitsch; Thomas Quertermous; Stephen B Montgomery; Joshua W Knowles; Ivan Carcamo-Orive
Journal:  Genome Med       Date:  2022-03-15       Impact factor: 15.266

6.  Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum.

Authors:  Marek Skrzypski; Paweł A Kołodziejski; Ewa Pruszyńska-Oszmałek; Tatiana Wojciechowicz; Paulina Janicka; Małgorzata Krążek; Emilian Małek; Mathias Z Strowski; Krzysztof W Nowak
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

7.  Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH.

Authors:  Laurianne Bonnet; Ida Alexandersson; Ritesh K Baboota; Tobias Kroon; Jan Oscarsson; Ulf Smith; Jeremie Boucher
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-22       Impact factor: 6.055

Review 8.  New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis.

Authors:  Georgiana-Diana Cazac; Cristina-Mihaela Lăcătușu; Cătălina Mihai; Elena-Daniela Grigorescu; Alina Onofriescu; Bogdan-Mircea Mihai
Journal:  Life (Basel)       Date:  2022-08-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.